These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32066976)

  • 1. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
    Ordonez AA; Wang H; Magombedze G; Ruiz-Bedoya CA; Srivastava S; Chen A; Tucker EW; Urbanowski ME; Pieterse L; Fabian Cardozo E; Lodge MA; Shah MR; Holt DP; Mathews WB; Dannals RF; Gobburu JVS; Peloquin CA; Rowe SP; Gumbo T; Ivaturi VD; Jain SK
    Nat Med; 2020 Apr; 26(4):529-534. PubMed ID: 32066976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.
    DeMarco VP; Ordonez AA; Klunk M; Prideaux B; Wang H; Zhuo Z; Tonge PJ; Dannals RF; Holt DP; Lee CK; Weinstein EA; Dartois V; Dooley KE; Jain SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5768-74. PubMed ID: 26169396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive
    Tucker EW; Guglieri-Lopez B; Ordonez AA; Ritchie B; Klunk MH; Sharma R; Chang YS; Sanchez-Bautista J; Frey S; Lodge MA; Rowe SP; Holt DP; Gobburu JVS; Peloquin CA; Mathews WB; Dannals RF; Pardo CA; Kannan S; Ivaturi VD; Jain SK
    Sci Transl Med; 2018 Dec; 10(470):. PubMed ID: 30518610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
    Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV.
    Requena-Méndez A; Davies G; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DA
    Antimicrob Agents Chemother; 2012 May; 56(5):2357-63. PubMed ID: 22330931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
    Perlman DC; Segal Y; Rosenkranz S; Rainey PM; Remmel RP; Salomon N; Hafner R; Peloquin CA;
    Clin Infect Dis; 2005 Dec; 41(11):1638-47. PubMed ID: 16267738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
    Peloquin CA; Maslow JN; Mikota SK; Forrest A; Dunker F; Isaza R; Peddie LR; Peddie J; Zhu M
    J Vet Pharmacol Ther; 2006 Dec; 29(6):581-5. PubMed ID: 17083464
    [No Abstract]   [Full Text] [Related]  

  • 15. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between sterilizing activity and drug distribution into tuberculosis lesions.
    Prideaux B; Via LE; Zimmerman MD; Eum S; Sarathy J; O'Brien P; Chen C; Kaya F; Weiner DM; Chen PY; Song T; Lee M; Shim TS; Cho JS; Kim W; Cho SN; Olivier KN; Barry CE; Dartois V
    Nat Med; 2015 Oct; 21(10):1223-7. PubMed ID: 26343800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
    Chirehwa MT; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; McIlleron H; Denti P
    Antimicrob Agents Chemother; 2016 Jan; 60(1):487-94. PubMed ID: 26552972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.